A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials.
David DejardinAnton KraxnerAnnika BlankNatascha RiederVolker TeichgräberNicolas StädlerUlrich BeyerBruno GomesJehad CharoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
We propose that a composite score of CD8+ T-cell density in paired biopsies taken before and on-treatment may be a new biomarker to inform on clinical outcomes in early immunotherapy clinical trials.